demeclocycline and Liver-Cirrhosis--Alcoholic

In five hyponatremic, cirrhotic patients, demeclocycline hydrochloride was used to inhibit the hydroosmotic effect of vasopressin. In four, renal impairment developed during the 7 to 20 days of demeclocycline hydrochloride (900 to 1,200 mg/day) administration. In these four patients, creatinine clearance fell (72 to 20 mL/min, P less than .01) as BUN (12 to 47 mg/dl, P less than .02) and serum creatinine (0.9 to 4.2 mg/dl, P less than .01) levels rose. The azotemic effect of the drug could not be accounted for consistently by volume depletion secondary to its natriuretic effect. However, a close correlation between plasma demeclocycline levels and its azotemic effect was observed. We conclude that a nephrotoxic effect of demeclocycline severly limits its usefulness in treating hyponatremia in the cirrhotic patient.

Topics: Adult; Creatinine; Demeclocycline; Glomerular Filtration Rate; Humans; Hyponatremia; Kidney; Kidney Diseases; Liver Cirrhosis, Alcoholic; Male; Natriuresis; Vasopressins

Topics: Demeclocycline; Humans; Kidney Failure, Chronic; Liver Cirrhosis, Alcoholic; Radioimmunoassay; Vasopressins

Topics: Aged; Demeclocycline; Humans; Hyponatremia; Liver Cirrhosis, Alcoholic; Male; Porphyrias